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1. Introduction 
1.1 Epidemiology of HPV 
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
worldwide that affects women as well as men. Around 75% of sexually active people will 
have an HPV infection at some point of life [1].  
HPV’s are small, non-enveloped DNA viruses and infect both cutaneous and mucosal 
squamous epithelia. They have been categorized as either low-risk types (lrHPV) or high-
risk types (hrHPV) depending on their oncogenic potential [2]. Following HPV types are 
considered as high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 68, 73, and 82. Types 26, 53, 
and 66 are considered as probable high risk (phr). The category low-risk HPV types are 
types 6, 11, 40, and 42. HPV type 67 is of undetermined risk. The most commonly detected 
types of HPV in cancers are 16 and 18 [1]. The most commonly detected HPV HPV in 
cancers are 16, 18 and 45. 
Most HPV infections are subclinical and transient in nature. A persistent oncogenic HPV 
infection has been found to be a necessary but insufficient risk factor in almost all cervical 
cancer cases [3] and an important risk factor in a subset of penile [4], vulvar, vaginal, and 
anal cancers [5], anogenital warts [6], recurrent respiratory papillomatoses [7, 8], and a 
fraction of head, and neck tumours [9, 10]. Table 1 [11]. 
Men are considered to carry the virus on them, function as a reservoir and act as transmitters 
of the virus. HPV DNA has been detected in samples of internal and external anogenital sites.  
Rintala found HPV in the vas deferens (18.5%): five of 27 vas deferens samples (of 
vasectomized men) contained HPV 6, 11, or 16 [12].  
Svec found HPV in the epididymis: lrHPV 6 and hrHPV 16, 33, 35, 55 and 73 were detected 
in the epididymis of 7/17 patients, treated with epididymectomy because of nontuberculous 
epididymitis [13].  
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Site and histological type Incidence (per 100,000) HPV DNA range (%) 
CERVIX 8-10 76-97 
VULVA 0.0-3.5  
VIN3  72-100 
Vulva warty-basaloid  75-100 
Vulva squamous  2-23 
VAGINA 0.0-1.5  
VAIN  82-100 
Vagina squamous  64-91 
PENIS 0.0-3.7  
PIN  90 
Penis warty-basaloid  46-100 
Penis squamous verrucous  31-35 
ANUS 0.1-2.8 males/0.0-2.2 females  
AIN  NA 
Anus squamous  >80 
OROPHARYNX & TONSILS 0.3-21.5 males/0.0-2.8 females 33-72 
VIN: vulvar intraepithelial neoplasia 
VAIN: vaginal intraepithelial neoplasia 
PIN: penile intraepithelial neoplasia 
AIN: anal intraepithelial neoplasia 
Table 1. Epidemiological traits of HPV and cancers. 
Martorell found HPV DNA in 12 testicular biopsies of 185 infertile men (6.5%). The HVP 
DNA was found in Leydig cells, in Sertoli cells, and probably in germinal cells [14]. Table 2 
Also the external anogenital areas have been extensively brushed to examine if these 
samples can be used to measure the presence of HPV DNA in a general population. Often 
they were combined with semen and urine samples, which are easy and painless to obtain. 
Furthermore, it was assumed that HPV DNA positivity in urine of semen reflected the 
presence of an  ‘’internal’’ HPV reservoir. 
HPV DNA is found on the foreskin, glans/coronal sulcus, penile shaft, scrotum, perianal 
region, urine, and urethra. Table 2 
Weaver found most HPV on the foreskin [15]. Giovannelli used penile brushes (PB), urethral 
brushes (UB), and semen (SE).  The HPV DNA detection rate in PB, UB, SE, PB and UB, and PB 
and SE were 88.9%, 50.0%, 33.3%, 100% and 97.2%, respectively. He concluded that the use of 
PB and UB appeared to be the most accurate method to screen; as an alternative to UB (which 
is a rather painfull swab), the use of SE with PB could be used to improve the detection rate 
[16]. Giuliano [17] examined penile shaft, glans penis/coronal sulcus, scrotum, urethra and 
semen and concluded that urethral swabs and seminal samples were adequate swabs, which 
contained sufficient human DNA and beta-Globin, but that HPV DNA presence was very low. 
She concluded that these two samples did not contribute to optimal sampling: exclusion of 
urethra, semen, scrotum and perinanal region resulted in a < 5% reduction in prevalence. 
Nielson [18] did extensive sampling of the anogenital region in healthy, heterosexual men and 
concluded that the more complete the sampling was, the more HPV DNA was found. 
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Secondly, she stated that anogenital HPV prevalence in asymptomatic men is higher than 
expected (previously). The penile shaft was most likely to be positive for HPV. 
Author Site 
HPV DNA 
(%) 
Types  
Rintala, 2002 Vas deferens 18.5 6, 11, 16 Post-vasectomy samples 
Svec, 2003 Epididymis 41.2 
6, 16, 33, 
35, 55, 73 
Nontuberculous epididymitis 
Martorell, 2005 Testis 6.5  
Testicular biopsies of infertile 
men 
     
Weaver, 2004 Penile shaft 24  Men attending STD clinic 
 Glans 16   
 Foreskin 28   
 Scrotum 17   
 Urine 6   
Giovannelli, 2007 Penile brushing 88.9  
Partners of HPV positive 
women 
 Urethral brushing 50.0   
 Semen 33.3   
Giuliano, 2007 Penile shaft 49.9  Heterosexual men 
 Glans penis/sulcus 35.8   
 Scrotum 34.2   
 Urethra 10.1   
 Semen 5.3   
Table 2. Anogenital sites and prevalence of HPV DNA 
2. HPV, semen and transport 
2.1 Interaction of semen and HPV 
The idea that sperm and seminal fluid could act as a vector for HPV transportation is not a 
new one. In 1979, epidemiological evidence had already suggested a correlation between 
some male penile cancers and female partner cervical carcinomas [19]. A few years later 
there was proof that male sexual partners of women with various benign or premalignant 
cervical lesions were at high risk for having penile lesions [20]. The incidence of HPV DNA 
in men is lower than in women, so questions rose about the possible modes of sexual 
transmission of HPV. Possibilities are that HPV DNA is present as free virus particles 
(virions) or is integrated in shed cells. Corollary questions are: 1)if the virus, once integrated 
in the cell’s DNA, can also express certain genes: 2) if the infected sperm cell can transfer 
HPV DNA into an embryo or to a sexual partner. 
To explore these questions Ostrow et al. (1986) examined the semen of patients with 
epidermodysplasia verruciformis and chronic lymphatic leukemia and found HPV 2 and 
HPV 5 [21]. About 95% of HPV DNA was found associated with extracts of the washes and 
not with the sperm pellet. They concluded that HPV DNA is not associated with the sperm 
itself, but is present as free HPV DNA or free virus particles. Green et al. (1989, 1991) 
demonstrated the presence of HPV DNA in the semen of patients with intrameatal and 
penile warts. They concluded that HPV DNA transmission occured from warts from which 
surface epithelial cells are shed during ejaculation [22, 23]. They found HPV DNA in the 
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pellet fraction and suggested that HPV DNA is associated with cellular material since 
virions are supposed to be found in the supernatant fraction of the semen. More recent 
studies confirmed convincingly the presence of HPV DNA in semen [16, 17, 18, 24]. 
Question 1 was approached by Lai et al. (1996): they wanted to examine the presence and 
expression of HPV in human plasma and sperm cells. They examined semen of 24 randomly 
selected patients who attended the Fertility Clinic. Type 16 E6-E7 DNA and RNA were 
found in 8.3 and zero % of seminal plasma specimens, respectively, and in 25 and 8.3% of 
sperm cells specimens, respectively. DNA and RNA sequences of HPV type 18 were found 
in 33.3 and 8.3% of seminal plasma specimens and in 45.8 and 20.8% of sperm cells 
specimens, respectively. They suggested that HPVs not only infect human sperm cells, but 
also succeed in expressing certain genes in the infected sperm cells [25].  
The second question was addressed by Chan et al. [26]. They developed an in vitro model 
that allowed sperm cells, carrying DNA fragments from HPV 16, 18, 31, and 33, from one 
end of an artificial reproductive tube and to come in contact with hatching mouse 
blastocysts at the other end of the tube. After washing the blastocysts were analyzed for the 
presence of foreign DNA fragments. Especially transference of DNA HPV type 18 to the 
blastocyst was shown. Not all DNA fragments were transferred equally. These results 
seemed to suggest that sperm can serve as a non-invasive gene delivery system to transport 
gene fragments into pre-implantation embryos. The fact that some parts of DNA were more 
easy to deliver, supports the assumption that a variety of factors and mechanisms are 
involved in transporting HPV DNA.   
Pao et al. (1996) examined the take up or retaining of different regions of HPV 18 by sperm 
cells [27]. They collected sperm samples of 23 subfertile men and found that the oncogenic 
regions of the viral genome were preferentially retained: 30% (E6) and 83% (E7), vs. 17% 
(upstream regulatory region), 22% (E1), and 4% (L1). 
In 2009, Perez-Andino et al. [28] compared the adsorption of HPV 16 to live human sperm 
cells in freshly ejaculated, undiluted human semen and in conditions that resemble the 
female genital tract. Fluorescent HPV 16 capsids were added to semen (concentration 80 
microg/l) and the mixture was incubated at 37oC. Even after several hours of incubation, no 
HPV 16 capsids were detected on the surface of sperm. When the vaginal environment (with 
a more acidic pH) was mimicked, viral binding was observed on 52% (pH 8.6) and on 72% 
(pH 7.4) of live sperm. Their conclusion was that association of HPV16 with sperm will 
probably not occur in neat semen, but may happen in the female genital tract, at low pH, 
following the dilution of the sperm. Furthermore they found that the HPV 16 capsids bind 
to two specific sites at the equatorial region of the sperm head surface. They suggested that 
by means of competitive binding on the virus, attachment to the sperm head may be 
inhibited. If applicable, this would be a way of protection of sperm cells, and consequently 
of blastocysts, of embryos, and of sexual partners.  
In 2011, Foresta et al. confirmed the binding of the virus at the equatorial region of the 
sperm head and demonstrated that this happened through interaction between the HPV 
capsid protein L1 and the receptor syndecan-1.Furthermore, they showed (using hamster 
egg-human sperm penetration test) that sperm transfected with HPV E6/E7 genes and 
sperm exposed to HPV L1 capsid protein are capable to penetrate the oocyte and transfer 
the virus into oocytes. Inside the oocytes, viral genes are activated and transcribed [29].  
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2.2 Effect of sperm washing 
Fertility clinics use washing methods to clean the sperm cells from unwanted viruses. 
However, HPV seems resistant and sperm washing does not eliminate HPV DNA. 
Olatunbosun [24] performed routine ‘’swim up’’ washing of 27 semen samples that 
contained HPV DNA: 21 samples were from men with genital lesions, six from sperm 
donors without prior or current HPV infection. Dodson[30] on the other hand, separated 
sperm cells by percoll gradient centrifugation in a 1ml aliquot and washed four times with 
sterile phosphate-buffered saline. All samples, coming from men with genital lesions, still 
contained HPV DNA after the washing procedure (100%). In six men, without genital 
lesions, the procedure reduced HPV DNA below detectable levels in only two (33.3%). 
Czegly [31] washed sperm cells in Percoll [Pharmacatia] or in Sperm RinseTM [Vitrolife] and 
found no change in HPV status.  
In 2011, Foresta and al. [32] performed semen analysis and in situ hybridization for HPV 
detection before and after sperm washing, discontinuous gradients, and swim-up protocols. 
Sperm washing centrifugation did not change the presence of HPV DNA; Ficoll density 
gradients and swim-ups brought about only a slight reduction. 
3. HPV, semen and fertility 
3.1 Effect on the sperm parameters 
The actual significance of HPV infection in sperm might be poorly understood and reports 
are conflicting, but it is a concern for those working in the field of reproductive medicine. 
Recent articles mention a negative influence on the quality of the sperm and on the 
pregnancy outcome.  
Connelly et al. [33] examined sperm samples of six subfertile patients. He found that specific 
sperm DNA fragmentation only occurred after exposure of the sperm to DNA of HPV types 
16 and 31.These viruses caused breakage characteristics of apoptotic but not necrotic sperm. 
His data suggest that these viruses do adversely affect subsequent embryonic development 
after fertilization. HPV DNA of types 6, 11, 18, and 33 did not compromise sperm DNA 
integrity: apparently sperm DNA is able to resist these types, or repairing mechanisms 
occur.  
In 1997 Lai [34] examined 24 samples of subfertile men for the presence of HPV DNA and 
RNA. HPV 16 DNA and RNA were found in 25% and 2% of sperm samples, respectively. 
HPV 18 DNA and RNA in 46% and 21%, respectively. The incidence of asthenozoospermia 
among patients infected with either HPV was significantly higher than in those without 
HPV in their sperm cells (75% vs. 8%). Performance of curvilinear velocity, straight-line 
velocity, and mean amplitude of lateral head displacement  was significantly lower in HPV-
infected specimens; the differences of linearity, beat cross frequency, and straightness were 
not statistically significant. Lai concluded: 1) that certain HPV-specific genes are actively 
transcribed; 2) that the presence of HPV in sperm cells may affect sperm motility 
parameters; 3) and that asthenozoospermia may be associated with sperm HPV infection. 
Recent studies (2009, 2010) by Foresta and al. confirmed these findings [35, 36].  
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 310 
In the first study he examined 200 samples from healthy, young volunteers. Ten persons had 
HPV DNA positive samples, which was associated with reduced sperm motility [35]. 
In the second study he collected 290 sperm samples from varying populations: patients with 
genital warts (n=26), HPV positive partners (n=66), infertile patients (n=108), and fertile 
controls (n=90). HPV semen infection in these groups was as follows: 53.8%, 40.9%, 10.2%, 
and 2.2%. The infertile patients had a higher prevalence of HPV DNA in their sperm 
samples than the other groups. Comparison of sperm parameters showed a more frequent 
reduction of sperm motility in infected samples, especially when the infection was present 
in the sperm itself [36].  
Rintala [37] examined sperm samples of 65 fathers-to-be; no assisted reproductive 
techniques (ART) were involved in the pregnancies. Ten men (15.4%) had seminal hrHPV 
DNA, without any affect on semen parameters such as semen volume, sperm concentration, 
motility and vitality of spermatozoa. No oligo- or asthenozoospermia was associated with 
seminal HPV DNA. However, there was a lowering of sperm pH in HPV DNA positive 
samples, with borderline statistical significance (7.4 vs. 7.5). Ejaculate acts as a potential 
alkaline buffer (pH 7.2-7.8) neutralizing vaginal acidity (pH 4.0-4.5) within seconds after 
ejaculation, keeping the vagina neutralized (pH 6.0-7.0) and semen motile. At pH 4.0, sperm 
cells are immobilized within one minute and are irreversibly immobilized and lose their 
vitality within 10 minutes [37]. 
3.2 Effect on pregnancy 
Nothing is known about the exact interference of an HPV positive sperm cell, injected in the 
oocyte cytoplasm (like during the ICSI procedure), with embryo development. Some studies 
mention an influence on the pregnancy outcome, while others do not find any different rates 
of spontaneous abortions and major birth defects in an HPV-exposed vs. an HPV-unexposed 
population [38]. 
Perino assessed the relation ship between HPV infection in 199 infertile couples and the 
outcome of ART. He found a significant correlation between pregnancy loss rate and 
positive HPV DNA testing in the male partner of infertile couples, compared with HPV 
negative male partners [39]. 
3.3 Effect on offspring 
Czegledy used six HPV positive sperm samples for in vitro fertilization (IVF) and intra- 
cytoplasmic sperm injection (ICSI). Three washed samples carried hrHPV 16. She tested the 
native sperm, the washed sperm cells, and the connected blastocysts for HPV sequences. All 
expectant mothers were HPV negative (negative PAP, negative colposcopy, negative HPV 
test). She found that (1) the washing procedures (Percoll [Pharmacatia] or Sperm RinseTM 
[Vitrolife]) did not change the HPV status of the sperm cells; (2) that HPV-positive 
spermatozoa kept their procreative capacity (gestation); (3) that HPV positive sperm cells 
create healthy offspring (follow-up 5 years) [31]. 
3.4 (Cryo)banking 
In an Italian cryobank, in 6/98 thawed samples of oncologic patients and in 2/60 samples of 
controls, HPV DNA was found.  Seven samples carried hrHPV’s 16, 18, 53 and 61. Only the 
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sperm head was infected by the virus [40]. Besides the possible effect of the presence of the 
virus on the sperm parameters, or on the offspring, or on the partners, another question was 
if HPV-infected sperm is able to cross-contaminate cryovials and impair also the outcome of 
ART of other couples or infect other partners. 
4. HPV, semen and cervical cancer 
Cervical cancer is the second most common malignancy among sexually active women 
worldwide. The pivotal, though insufficient, role of persistent oncogenic HPV infection in 
almost all cancer cases (99.7%) is well established. Factors in the acquisition of HPV are 
related to sexual behavior: young age at sexual debut and multiple sexual relations. Still, it 
usually takes several decades between the initial HPV infection and the onset of cervical 
cancer.  
Wang (2010) postulated that human semen may play a role in genital transmission of HPV 
and in cervical carcinogenesis itself, based on the following arguments [41]. 
- Intact genital epithelium is resistant to HPV infection. Tiny tears are necessary to make 
passage of HPV particles to the basal epithelial cell surface possible, and to initiate 
infection. Besides spermatozoa semen also contains various chemical components, 
which may be able to disrupt the normal architecture of cervical epithelium [42].  
- Secondly, the immunosuppression of human semen allows interaction with the female 
and the zygotes. The cell-mediated immunity is considered as the major protection 
against HPV infection [43]. So, it is possible that semen-mediated immunosuppression 
may facilitate HPV transmission and/or may reactivate latent HPV infection. 
- Chronic inflammation is generally considered a major risk factor for most cancers [44]. 
Prostaglandins are present in semen at 10,000-fold higher concentrations than those 
detected at the site of inflammation with PGE2 being the predominant type [45]. Up-
regulated PGE2-synthesis is regarded as a possible promoter of cervical carcinogenesis 
[46]. Consequently, in sexual active women, repeated exposure of HPV infected cervical 
epithelial cells to high concentrations of PGE2, may be seen as a paracrine modulation 
of cervical carcinogenesis. 
- Degradation of the extracellular matrix by matrix metalloproteinases (MMP’s) is 
essential to tumor invasion and metastasis [47]. Semen has the capacity to stimulate the 
production of messenger ribonucleic acid (m-rna) for MMP-9 [48], which is correlated 
with the invasive behavior of cervical cancer [49]. 
- Furthermore, as mentioned above, HPV capsids could adsorb to spermatozoa, which 
are highly motile to traverse the thick mucus layer in the female genital tract [28]. 
However, this hypothesis is in conflict with the first results published on this issue by 
Nieminen et al. They did not find (dot blot DNA hybridization) any HPV DNA in the sexual 
partners of 27 women positive for HPV DNA [50]. The method used for the processing of 
the samples can be an explanation. 
5. Study in the Fertility Clinic of the University Hospital of Antwerp 
From the above observations, it is clear that sperm cells may be necessary co-promotors of 
cervical carcinogenesis and that they compromise male fertility. 
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Furthermore, we wanted to objectify the presence of HPV in sperm samples of subfertile 
men and of sperm donors. 
5.1 Materials and methods 
The study protocol was approved by the local Ethics Committee (UA A08 22). 
Written informed consent was obtained from all couples/sperm donors. 
5.2 Semen samples 
Samples were obtained from 41 subfertile men and 21 sperm donors.  All samples had been 
approved for IVF/IUI and ICSI procedures. They were submitted to real time-PCR to 
determine the presence of 18 HPV types. 
5.3 Semen collection and analysis 
Samples were collected after 3-6 days of sexual abstinence by masturbation. After 
liquefaction, a basic semen analysis was performed and scored according to World Health 
Organisation (WHO 1992) guidelines. These guidelines were adopted after successful 
training of lab technicians via ESHRE (European Society for Human Reproduction and 
Embryology) Basic Sample Analysis Courses. Quality assurance was guaranteed by 
applying standardized methods accompanied with regular internal and external quality 
controls.  
5.4 Semen processing 
A part of the semen sample was treated with a two-step discontinuous density gradient [51] 
using Puresperm® (Nidacon, International AB, Gothenburg, Sweden). Briefly, 40% and 80% 
Puresperm® density gradient were prepared using 1.0ml of each suspension. Semen was 
layered on the top of each gradient and centrifuged for 15 mins at 300g. After which the 
upper layer seminal plasma and the 40 – 80% interface were discarded and the remaining 
spermatozoa in the 80% pellet was collected from the bottom of the tube and washed once 
with Earle’s Balanced Salt solution (EBSS, Life Technologies, Paisley, Scotland) 
supplemented with sodium pyruvate (0.011 g/l) and penicillin-streptomycin (50,000 units/l 
and 50,000 µg/l, Life Technologies, Paisley, Scotland). Samples were kept at -20°C. 
5.5 DNA extraction 
DNA is bound to the surface of carboxylated magnetic particles under conditions of high 
polyethylene glycol and salt concentrations (Magnetic Beads extraction Abott M 2000), 
following the manufacturer’s instructions [52]. Briefly, Abbott RealTime HR HPV test 
procedure consists of sample preparation, reaction assembly, real-time PCR, and result 
reporting. During sample preparation, 0.4mL of sample is processed using the Abbott 
mSample Preparation SystemDNA where sample is lysed with chaotropic reagents, and 
DNA is captured with magnetic microparticle technology. Unbound sample components 
and inhibitors are washed away and the bound purified DNA is eluted and is ready for 
amplification. Abbott RealTime HR HPV is currently validated for use with cervical 
specimens collected in PreservCyt solution (Hologic Inc., Marlborough, MA, USA). 
www.intechopen.com
 
Human Papillomavirus in Donor Semen in Belgium 313 
Specimens can be transported at room temperature or refrigerated, and may be stored up to 
4 months at room temperature or up to 6 months refrigerated or at 10°C or colder following 
collection. At the completion of sample preparation, an amplification master mix is created 
with AmpliTaq Gold enzyme (Roche Molecular Systems, Inc. Branchburg, NJ, USA), 
magnesium chloride, and oligonu- cleotide reagent containing primers, probes and dNTPs. 
As a preparation method we used the fully automated m2000sp for medium-to-high test 
volume that processes up to 96 samples in a run.. 
5.6 Real time quantitative PCR analysis of HPV DNA 
Presence of 18 different HPV geno-types was determined using TaqMan-based real-time 
quantitative PCR’s targeting type specific sequences of viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 
E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58 E6, 59 E7, 66 E6, 67 L1 and 68 E7. 
Analytical sensitivity of the different PCR assays ranged from 1-100 copies and was calculated 
using standard curves for 16 type-specific PCRs constructed with plasmids containing the 
entire genome of the different HPV types [53].  Real-time quantitative PCR for ß-globin was 
always performed and was used to verify the quality of DNA in the sample and to measure 
the amount of input DNA [54]. The amount of ß-globin DNA (in nanograms) present in each 
sample was divided by the weight of 1 genome equivalent (i.e., 6.6 pg/cell) and a factor of 2 
(since there are 2 copies of ß-globin DNA / cell) to obtain the number of genome equivalents 
in the sample. Viral loads in each specimen were expressed as the number of HPV copies / 
cell. The 18 HPV types we tested for were divided according to Munoz [55] 
5.7 Questionnaire and screening 
Standard questionnaire with questions about: 
•  Life style: use of tobacco, alcohol, and drugs 
• Sexual history: Number of partners during the past 6 months, homosexual partners, 
anal sexual activities, SOI.  
• Motivation to donate sperm. 
Routine: 
•  screening for HIV, Hepatitis B, Hepatitis C, Syphilis, Chlamydia trachomatis, Neisseria 
gonnorhea. 
• HBA1C, FSH, Testosteron, SHBG, Inhibine B 
6. Results 
All samples were adequate and contained sufficient beta-Globin. In the native sperm of two 
patients high risk HPV type 39 was found: one in a sample of a man visiting the fertility 
clinic, one in a sample of a sperm donor. In the gradient specimens, no HPV DNA was 
found. 
7. Discussion  
Investigation of sperm in our fertility clinic resulted in only 2 HPV DNA positive samples, 
out of 82.  Our samples came from subfertile, but healthy men and sperm donors. Foresta 
[40] found a significant number of HPV DNA in thawed sperm samples from patients with 
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testicular cancer (6.1%), when compared to the samples of controls (93.3%). The HPV types 
involved in the patients were 4x hrHPV, 1 medium-risk HPV, and 1 lrHPV. 
Questions concerning HPV DNA in a cryobank are whether the virus can cross-contaminate 
other vials and if contamination has clinical consequences for the outcome of the ART, and for 
the health of the offspring and the receiving partner. To answer these questions, more research 
is needed to understand more about the exact interaction of the human papillomavirus with 
sperm cells and the clinical consequences of (the use of) HPV positive sperm cells. 
We feel that, at this moment, routine screening of sperm for HPV, will not contribute to the 
safety of the procedure. 
8. Overall conclusion 
Research on the prevalence of HPV DNA in semen and its effect on sperm quality and 
pregnancy outcome is growing. 
It seems that the lower pH in the vaginal environment has a double effect: it increases the 
capacities of the virus to adsorb to sperm cells.  Consequently it affects capacities of the 
sperm cells in a negative way, especially the motility. Other studies mention consequent 
problems with embryogenic development and a worse outcome of pregnancies [39]. 
Therefore, it has been suggested to discourage the use of fresh semen for artificial donor 
insemination program, until accurate, rapid diagnostic tests are available to exclude the 
presence of HPV infection, and to us only frozen semen that has been appropriately 
screened [24]. 
Some author’s hypothesized that the presence of HPV in semen may be a co-risk factor for 
women to develop, cervical cancer, later on in life. Therefore, they promote the use of 
condoms to prevent genital transmission of HPV and reduce the incidence of cervical cancer 
[41]. This advice is difficult to follow for couples with a long-lasting, monogamous sexual 
relationship. 
The conclusions of the different studies are not unanimous and further research has to focus 
on the mechanisms involved, the clinical consequences, and on the  prevalence of these 
problems. 
Furthermore, the number of women vaccinated with one of the prophylactic vaccines is 
growing. This protection may reduce the possible risks, caused by the presence of HPV 
DNA in semen. Wise examined the effect of the prophylactic quadrivalent vaccine on 
reproductive organs and semen. He vaccinated male and female rats. All rats had a specific 
antibody response to the four types after each injection. There were no effects on the 
reproductive parameters of cohabited male rats: they had normal sperm count and sperm 
motility. Also the histomorphology of testis and epididymis were unchanged [56].   
The vaccine will probably cause no harm to the fertility of its users, and will in addition, 
provide protection for the development of cervical lesions [57]. 
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